

ASX Announcement

17 September 2026

RECEIPT OF SECTION 249D NOTICE FROM BCAL DIAGNOSTICS

Genetic Signatures Limited (ASX: GSS) (GSS or the Company) advises in accordance with ASX Listing Rule 3.17A, that it has received a request from BCAL Diagnostics Limited pursuant to section 249D of the Corporations Act for the directors of GSS to call and arrange a general meeting of shareholders for the purposes of considering the following resolution:

“That Jenny Harry be removed as director of the Company immediately following the passing of this resolution.”

GSS is considering the section 249D notice and, if it considers the notice to be valid, GSS will comply with its relevant obligations under the Corporations Act and will undertake the necessary steps to convene a general meeting.

– END –

Announcement authorised by Genetic Signatures Limited’s Board of Directors.

For further information, see our website (www.geneticsignatures.com) or contact us:

Mike Aicher

Chair, Genetic Signatures Limited
mike.aicher@geneticsignatures.com
T: +61 (0)2 9870 7580

Maria Halasz

CEO, Genetic Signatures Limited
maria.halasz@geneticsignatures.com
T: +61 (0)2 9870 7580

About Genetic Signatures

Genetic Signatures is a specialist molecular diagnostics company focused on the development and commercialisation of its proprietary platform technology, 3base®. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the EasyScreen™ brand. Genetic Signatures’ proprietary 3base® platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures’ current target markets are major hospital and pathology laboratories undertaking infectious disease screening.